Archive


Category: Beckley Psytech

  • Beckley adds digital element to its psychedelic drug trials

    Phase 2 trials of Beckley Psytech’s psychedelic drug candidates will make use of digital technologies for patient monitoring, thanks to a new partnership with Empatica. The Oxford, UK-based drug developer said it will make use of Empatica’s wearable devices and software in its studies to enrich the data it can harvest from them and hopefully […]

  • Psychedelics startup Beckley attracts Janssen neuroscience VP

    Psychedelic medicines specialist Beckley Psytech has enticed a senior figure in Janssen’s neuroscience division to take on the role of its chief medical officer as it ushers its first drugs through clinical trials. Dr Frank Wiegand is joining Beckley after more than two decades at Janssen and parent company Johnson & Johnson, most recently as […]

  • First subject dosed in psilocybin trial for rare headache disorder

    The first patient has received a low dose of Beckley Psytech’s psychedelic medicine psilocybin in a clinical trial for short-lasting unilateral neuralgiform headache attacks (SUNHA), a rare disorder. The UK company says that SUNHA is a debilitating condition that is estimated to affect 40,000 patients in US and Europe. It is characterised by short, extremely […]

  • Beckley Psytech raises $80m for psychedelic meds development

    UK psychedelic medicine specialist Beckley Psytech has raised an impressive £58 million (around $80 million) in an oversubscribed second-round financing that will help fund clinical development of its psilocybin-based therapies. The Oxford-based company had originally hoped to raise $50 million from the series B, and the scale of the financing is further evidence that repurposing […]